Calendar

A Science & Innovation Webinar, presented by Lilly.

Alzheimer's disease begins years before symptoms appear and progresses along a continuum. This session reviews the clinical stages of AD and why recognizing each stage matters for patients.

• Describe the stages of the AD continuum.
• Explain how underlying AD pathology accumulates and advances.
• Identify the patient, caregiver, and health system implications of progression across each stage.

A Science & Innovation Webinar, presented by Abbvie.

The objective of this Pharmacokinetic/Pharmacokinetic (PK/PD) analysis is to evaluate Bruton's Tyrosine Kinase (BTK) occupancy at doses included in the US Prescribing Information (USPI) dose modifications for adverse reactions recommendations.

• Review the dose modification guidance for adverse reactions included in the US Prescribing Information.
• Explain the PK/PD findings showing BTK occupancy at doses included in the USPI dose modifications for adverse reactions.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Genentech.

Join us for a Pre-Approval Information Exchange (PIE) on giredestrant, an investigational oral SERD under evaluation for adjuvant ER+/HER2- stage I–III breast cancer at intermediate to high-risk of recurrence. This session reviews eBC disease burden, clinical parameters from the Phase 3 lidERA study, and population-level Treatment Impact Model (TIM) considerations to assist payers with early budget and health plan forecasting.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Apnimed.

Obstructive Sleep Apnea (OSA) is common, costly, and rarely just sleep apnea — it raises cardiovascular, metabolic, and neurocognitive risk. Decades under the medical benefit, OSA therapies mechanically target obstruction instead of a key neuromuscular cause. This PIE webinar previews the neuromuscular mechanism behind airway collapse, gaps in the current landscape, and a new approach targeting airway muscle tone. Learn about an investigational oral therapy before it hits your P&T agenda.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have note been established.

An AMCP Market Insights Webinar.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare immune-mediated neuropathy that can result in significant long-term disability if diagnosis and treatment are delayed. In this AMCP Market Insights webinar, Dr. Ehtesham Khalid reviews recent advances in the understanding of CIDP, including emerging insights into disease pathophysiology, diagnostic challenges, current standards of care, and investigational therapies. Drawing on findings from AMCP's May 2026 Market Insights roundtable, the program highlights issues relevant to managed care professionals, including treatment timing, evolving mechanisms of action, and considerations for future coverage and access decisions.

An AMCP CE Webinar.

Through a moderated panel discussion featuring experts from managed care, industry, and health policy, speakers will examine key themes related to the value, communication, credibility, and application of Patient Experience Data in coverage and formulary decision-making. The session will conclude with practical recommendations and future directions for advancing the meaningful use of patient experience data in payer decision-making.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Intellia Therapeutics.

This presentation contains information about the investigational product lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002) for the treatment of hereditary angioedema (HAE). Lonvo-z is investigational, has not received FDA-approval, and safety and efficacy have not been established. This presentation is intended only for payers, formulary committees or other similar entities responsible for the selection of drugs for coverage or reimbursement.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by Abbvie.

It is important to appropriately manage a person with migraine who experiences greater than 4 attacks a month (or severe disability from at least two attacks a month) and may benefit from preventive therapy. One of the main goals of preventive therapy is to improve function and reduce disability. Utilizing a stratified care approach to preventive migraine treatment is key to accomplish this goal.

Dr. Maureen Moriarty, a migraine expert, will:

• Discuss the complexity of migraine disease and the burden of the disease as it relates to function.

• Discuss the treatment guidelines for preventive treatment of migraine, with a focus on a treatment option with updated clinical data for migraine prevention.

An AMCP Member Webinar.

Join AMCP for a timely post-election webinar examining how the results of the 2026 elections may shape the future of health care policy. This session will provide an overview of key federal priorities expected to emerge in the new political landscape. Expert speakers will discuss how shifts in congressional and administrative leadership could influence legislative and regulatory activity, coverage policies, and patient access to medications.

An AMCP Virtual CPE Event.

10-11am ET: Satellite Symposium: Reducing Nonadherence and Rehospitalization Through Effective Tardive Dyskinesia Treatment

12-1pm ET: Precision at Scale: Translating the Evolving Biomarker Landscape in NSCLC Into Strategies for Timeline and Targeted Care

2-3:15pm ET: Oncology Pipeline 2026: Advances, Trends, and Impact

4-5:30pm ET: Satellite Symposium: Navigating Payer Decisions in an Evolving Multiple Myeloma Treatment Landscape

A Science & Innovation Webinar, presented by Abbvie.

One of the primary goals of acute treatment of migraine is rapid and consistent freedom from pain and most bothersome associated symptoms without recurrence. Regardless of migraine frequency or time of month, it is important that every appropriate person with migraine be offered a treatment for migraine. Notably, over 50% of females with migraine disease experience migraine attacks around menstruation, which can be more severe, and longer-lasting than those occurring at other times of the month. The objective for this webinar is to review the migraine disease state and outline the clinical data for an acute treatment of migraine attacks, including data around the perimenstrual period.

Dr. Deena Kuruvilla, a headache specialist, will:

• Discuss the complexity of migraine disease and the burden of the disease as it relates to function.
• Discuss an acute treatment option for migraine in adults.

An AMCP CPE Webinar.

The therapeutic landscape for dyslipidemia is rapidly evolving, with recently approved agents and a robust pipeline of novel medications targeting LDL-C, triglycerides, Lp(a), and cardiovascular risk reduction. This session examines key updates from the 2026 ACC/AHA Guideline on the Management of Dyslipidemia and provides a comprehensive overview of newly FDA-approved therapies—including APOC3-targeted agents for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), and PCSK9 inhibitors—alongside emerging late-stage pipeline medications such as oral PCSK9 inhibitors, CETP inhibitors, and Lp(a)-lowering therapies. Participants will compare the latest clinical evidence across these innovations and explore their implications for formulary decisions, utilization management strategies, patient access, and cost considerations.  

This session equips managed care professionals with the clinical and economic insights needed to evaluate and integrate next-generation lipid management therapies into evidence-based coverage frameworks.